

DAFTAR PUSTAKA

- Aritonang J, Rasyid N, Rodjani A, Mochtar CA, Umbas R, Hamid AR. Relation between Benign Prostatic Hyperplasia (BPH) and Hormone Level Status. Department of Urology, Faculty of Medicine, Universitas Indonesia and Cipto Mangunkusumo Hospital, Jakarta, Indonesia. Unpublished review. 2014.
- Barkin, J. 2011. Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms: Evidence and Approach for Best Case Management. *The Canadian Journal of Urology* 18: 14-19.
- Brewster S, Cranston S, Noble J, and Reynard J. *Urological Oncology*. 2001. In : *Urology: A Handbook for Medical Students*. UK: BIOS Scientific Publisher Limited: 143-150.
- Briganti A, Capitanio U, Suardi N. Benign Prostate Hyperplasia and its Aetiologies. (2009).
- Byun KH, *et al*. Relationships between Prostate-Specific Antigen, Prostate Volume, and Components of Metabolic Syndrome in Healthy Korean Men. *Korean Journal of Urology* (2012).
- Dayspring T. Understanding The Entire Lipid Profile.
- Deters, LA, 2013. Benign Prostatic Hypertrophy. Available from: <http://emedicine.medscape.com/article/437359-overview#a0156>[Accessed 29 Januari 2014].
- European Association of Urology. Guidelines on Benign Prostatic Hyperplasia. 2006.
- Gokce, A *et al*, 2010. The Relationship Between Serum Lipid Level and Benign Prostate Hyperplasia. *The New Journal of Medicine*: 148-150
- Gupta A, Gupta S, Pavuk M, Roehrborn CG. Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. *Urology* 2006;68: 1198-205.
- Haffner S, Taegtmeier H. Epidemic Obesity and Metabolic Syndrome. (2003): 1541-1545.
- John, T. *et al*., 2010. *Netter's Clinical Anatomy* 2nd edition. Philadelphia. Saunders Elsevier inc : 200.

- Jonas A, Rosenblat G, Krapf D, et al: Cactus Flower extracts may prove beneficial in benign prostatic hyperplasia due to inhibition of 5 alpha reductase activity, aromatase activity and lipid peroxidation. *Urol Res* 26: 265-270, 1998.
- Kee JL. *Laboratory and Diagnostic Tests with Nursing Implications*. 6th ed. Upper Saddle River, NJ: Prentice Hall; 2002.
- Lagiou P, Wu J, Trichopoulou A, et al: Diet and benign prostatic hyperplasia: a study in greece. *Urology* 54: 424-428, 2004.
- Lekili M, Muezzinoglu T, Uyanik BS, Buyuksu C. Serum lipid levels in benign prostatic hyperplasia. *World J Urol* 2006;24: 210-3.
- Lepor H, M.D. *Pathofisiologi, Epidemiology and Natural History of Benign Prostate Hyperplasia* (2004).
- Mc Vary KT. The Definition of Benign Prostatic Hyperplasia: Epidemiology and Prevalence. In: *Management Of Benign Prostatic Hypertrophy*. New Jersey: Humana Press. 2004: 21-27.
- Meigs JB, Mohr B, Barry MJ, et al: Risk Factors for Clinical Benign Prostatic Hyperplasia in a community-based population of healthy aging men. *Journal of Clinical Epidemiology* 54: 935-944, 2001.
- Mohammed MM, Abdulridha KM, Mustafa Y, Al-Mullahumadi K. Body Mass Index (BMI), Lipid profile, Leptin and Their Correlation with Prostatic Specific Antigen (PSA) in Iraqi patients with Benign Prostatic Hyperplasia (BPH), (2012).
- National Cholesterol Education Program, *Lipid Risk Categories Revised* May (2001).
- Neuhouser ML, Kristal AR, and Penson DF; Steroid hormones and hormone related genetic and lifestyle characteristic as risk factors benign prostatic hyperplasia: a review of epidemiologic literatur. *Urology* 64: 201-211, 2004.
- Parikesit D, Mochtar CA, Umbas R, Hamid ARAH. The impact of obesity towards prostate diseases. Department of Urology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia. Unpublished review. 2014.
- Parsons KJ, *et al*. Metabolic Factors Associated with Benign Prostatic Hyperplasia. *The Endocrine Society* (2006).
- Parsons KJ, *et al*. Lipids, Lipoprotein, and Risk of Benign Prostatic Hyperplasia in Community Dwelling Men. (2008).

- Philip, M. *et al.*, 2007. Hanno, M.D., Alan J. Wein, S. Bruce Malkowicz, M.D. Prostatitis in Penn Clinical Manual of Urology. Elsevier Health Sciences.
- Potts MJ, *et al.* Essential Urology. (2004) 191-202.
- Presti, JC. *et al.*, 2008. Kane CJ, Shinohara K, Carroll PR. Neoplasms of the prostate gland. Dalam: Smiths's General Urology. 17th edition. California: McGrawhill. p. 348-355.
- Rahardjo D, 1999. Prostat: Kelainan-kelainan jinak, diagnosis, dan penanganan. Jakarta: Asian Medical, 15.
- Rahardjo D., 2009. Prostat Hipertrofi. Dalam: Kumpulan kuliah ilmu bedah. Jakarta: Binarupa Aksara; h 160-168.
- Ranjan P. *et al.*, 2006. Diet and Benign Prostatic Hyperplasia : Implication for Prevention.
- Roehrborn, CG. *et al.*, 2010. McConnell JD. Benign Prostatic Hyperplasia: Etiology, Pathophysiology, Epidemiology, and Natural History in Campbell - Walsh Urology. 10th edition. Philadelphia: Elsevier Saunders.
- Sarma AV and Wei JT. Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms. The New England Journal of Medicine. 2012; 367: 248-257.
- Soeharto, I (2004) Serangan Jantung Dan Stroke Hubungannya dengan Lemak dan Kolesterol. Jakarta : PT Gramedia Pustaka Utama
- Soygur T, Kupeli B, Aydos K, et al: Effect of obesity on prostatic hyperplasia: its relation to sex steroid levels. Int Urol Nephrol 28: 55-59, 1996.
- Sudigdo S. Dasar-Dasar Metodologi Penelitian Klinis Edisi 4 (2011).
- Suzuki S, Platz EA, Kawachi I, *et al*: Intakes of Energy and Macronutrients and Risk of Benign Prostatic Hyperplasia. The American Journal of Clinical Nutrition 75:689-697, 2002 .
- Tewari R, Rajender S, Shanker M, *et al.* Diet, Obesity and Prostate Health: Are we missing link ?. (2012). Syndrome. (2009).
- Tong YC. Male Lower Urinary Tract Symptom / Benign Prostatic Hyperplasia and Metabolic
- The American Urological Association, I-PSS Symptom Index (2011).

- van der Sluis TM, Meuleman EJ, van Moorselaar RJ, Bui HN, Blankenstein MA, Heijboer AC, et al. Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer. *BJU international*. 2012;109(2):183-8.
- Vikram A, Ramarao P. Lipids in The Pathogenesis of BPH: emerging connections, (2010).
- Wein, Kavoussi, Novick, Partin, Peters. *Campbell-Walsh Urology Ninth Ed.* Philadelphia: Saunders-Elsevier: 2007.
- Weisser H, Zeimssen T, and Kreig M: Phospholipase A2 degradation products modulate epithelial and stromal 5 alpha reductase activity of human benign prostatic hyperplasia in vitro. *Prostate* 50: 55-59, 1996.
- Williams NS, Bulstrode CJK, O'Connell PR. TBaihe Prostate and Seminal Vesicles. In: *Bailey & Love's Short Practice of Surgery 26th Edition*. New York: CRC Press: 2013; 1340-1353.